2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-76251S1
    (rac)-Etodolac-d3 1276197-46-6
    (rac)-Etodolac-d3 is a labelled racemic Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)
    (rac)-Etodolac-d3
  • HY-B0004S1
    Doxofylline-d4 1346599-13-0
    Doxofylline-d4 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV[1][2].
    Doxofylline-d4
  • HY-B0574S1
    Mefenamic Acid-d3 1189707-81-0
    Mefenamic Acid-d3 is the deuterium labeled Mefenamic acid. Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of hCOX-1 and hCOX-2, with IC50s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.
    Mefenamic Acid-d3
  • HY-20587
    CRAC intermediate 1 1249343-86-9 98.46%
    CRAC intermediate 1 is a key intermediate in the chemical synthesis of a series of CRAC channel inhibitors, detailed information can be found in Patent WO 2010122089 A1, intermediate 9.
    CRAC intermediate 1
  • HY-P0260
    p2Ca 142606-55-1
    p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.
    p2Ca
  • HY-P0266
    N-Acetyl-Ser-Asp-Lys-Pro 127103-11-1
    N-Acetyl-Ser-Asp-Lys-Pro, an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of ACE.
    N-Acetyl-Ser-Asp-Lys-Pro
  • HY-P0273
    Histatin 5 115966-68-2
    Histatin 5 inhibits the activity of the host matrix metalloproteinases MMP-2 and MMP-9 with IC50s of 0.57 and 0.25 μM, respectively.
    Histatin 5
  • HY-P0284
    C-telopeptide 162929-64-8
    C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).
    C-telopeptide
  • HY-101655
    COX-2-IN-2 134729-13-8 99.53%
    COX-2-IN-2 is a selective and inducible COX2 inhibitor with an IC50 of 0.24 μM. COX-2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.
    COX-2-IN-2
  • HY-103637
    Vimirogant 1802706-04-2
    Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research.
    Vimirogant
  • HY-U00157
    Meseclazone 29053-27-8
    Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.
    Meseclazone
  • HY-U00169
    Prednisolone farnesylate 118244-44-3
    Prednisolone farnesylate (PNF21) is a new transdermal corticosteroid with anti-inflammatory activity.
    Prednisolone farnesylate
  • HY-U00187
    NCX1022 571186-50-0
    NCX1022 is an NO-releasing derivative of Hydrocortisone, which is the most widely used anti-inflammatory agent for the treatment of skin inflammation.
    NCX1022
  • HY-U00210
    D18024 110406-33-2
    D18024 is a phthalazinonderivat antiallergic and antihistaminic activity.
    D18024
  • HY-U00252
    ONO4057 134578-96-4
    ONO4057 is a Leukotriene B4 receptor antagonist, with an IC50 of 0.7±0.3 μM.
    ONO4057
  • HY-U00275
    COX-2-IN-1 787623-48-7
    COX-2-IN-1 is potent and slective COX-2 inhibitor with an IC50 of 3.9 μM.
    COX-2-IN-1
  • HY-U00305
    Cicloxilic acid 57808-63-6
    Cicloxilic acid is a biologically active agent.
    Cicloxilic acid
  • HY-U00412
    Asthma relating compound 1 120165-51-7
    Asthma relating compound 1 is an anti-asthmatic agent candidate extracted from patent EP0295656A1.
    Asthma relating compound 1
  • HY-101831
    Heterocyclyl carbamate derivative 1 168830-01-1
    Heterocyclyl carbamate derivative 1 is a heterocyclyl carbamate derivative that may be used for the research of inflammatory and neurological diseases.
    Heterocyclyl carbamate derivative 1
  • HY-19205A
    CMI-392 205654-37-1
    CMI-392 is a dual 5-lipoxygenese inhibitor and platelet-activating factor (PAF) receptor antagonist with IC50s of 100 and 10 nM, respectively.
    CMI-392
Cat. No. Product Name / Synonyms Application Reactivity